Can Myovant Sciences Limited (NYSE:MYOV)’s Tomorrow be Different? The Stock Had Increase in Shorts

July 17, 2017 - By Linda Rogers

 Can Myovant Sciences Limited (NYSE:MYOV)’s Tomorrow be Different? The Stock Had Increase in Shorts

The stock of Myovant Sciences Limited (NYSE:MYOV) registered an increase of 16.78% in short interest. MYOV’s total short interest was 638,800 shares in July as published by FINRA. Its up 16.78% from 547,000 shares, reported previously. With 100,200 shares average volume, it will take short sellers 6 days to cover their MYOV’s short positions.

About 5,519 shares traded. Myovant Sciences Ltd (NYSE:MYOV) has 0.00% since July 17, 2016 and is . It has underperformed by 16.70% the S&P500.

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical firm focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. The company has market cap of $690.96 million. The Company’s main product candidate is Relugolix. It currently has negative earnings. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.

More notable recent Myovant Sciences Ltd (NYSE:MYOV) news were published by: which released: “BRIEF-Myovant Sciences announces initial pricing of 14.5 mln common at $15/shr” on October 27, 2016, also with their article: “Myovant Sciences Announces Appointment of Board of Directors” published on October 12, 2016, published: “Roivant Sciences and Takeda Launch Myovant Sciences to Develop Innovative …” on June 06, 2016. More interesting news about Myovant Sciences Ltd (NYSE:MYOV) were released by: and their article: “Myovant Sciences Announces Upcoming Presentations of Relugolix Data from Phase …” published on May 18, 2017 as well as‘s news article titled: “Myovant Sciences Appoints Terrie Curran to Board of Directors” with publication date: November 16, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.